Ectopic expression of GLP-1 receptors in liver cells combined with peptide agonist treatment enhanced energy expenditure and weight loss beyond peptide treatment alone in obese mice.
Boosted energy expenditureLiver GLP-1R expression + peptide agonist increased energy burning beyond what peptide drugs achieve alone
What the researchers found
AAV-mediated ectopic GLP-1R expression in hepatocytes combined with semaglutide or dual GLP-1R/GIPR agonist treatment enhanced energy expenditure and weight loss compared to peptide treatment alone in diet-induced obese mice.
Why it matters
This proof-of-concept shows a novel approach to achieving the energy expenditure benefits of triple agonists without the cardiovascular risks of glucagon receptor activation.
How the study worked
Adeno-associated virus (AAV) delivery of liver-specific GLP-1R in wild-type diet-induced obese mice, followed by treatment with semaglutide, NNC5840 (cAMP-biased GLP-1R analogue), or dual GLP-1R/GIPR agonist, with energy expenditure and weight monitoring.
What this study cannot tell us
Mouse model only. AAV-mediated gene therapy adds complexity and cost. Long-term effects of ectopic hepatic GLP-1R expression unknown. Not immediately translatable to clinical use.
How to read the evidence
Novel proof-of-concept in mice with multiple agonist validations. Early-stage but mechanistically sound.
When this study was published
Published in 2025.
The bigger picture
This gene therapy + peptide drug combination approach represents a new frontier in obesity treatment that could overcome the safety limitations of current multi-receptor peptide agonists.
Questions still open
- Could liver-targeted GLP-1R gene therapy become a viable clinical strategy?
- What are the long-term effects of ectopic GLP-1R expression in hepatocytes?
- Could mRNA-based approaches replace AAV for transient liver GLP-1R expression?
Common questions
Why add GLP-1 receptors to the liver?
Could this become a treatment?
Read the original research
Ectopic, hepatic GLP-1R agonism enhances the weight loss efficacy of GLP-1 analogues.
Molecular metabolism, 105, 102327
Citation
Douros, Jonathan D; Capozzi, Megan; Novikoff, Aaron; Mokrosinski, Jacek; DuBois, Barent; Stock, Joseph; Rohlfs, Rebecca; Anderson, Mikayla; Jedrzejcyk, Dominika J; Poulsen, Svend; Blenke, Erik Oude; Dago, Tomas; Huus, Kasper; Nørby, Peder L; Kobberup, Sune; Rivir, Marita; Sorrell, Joyce; Mowery, Stephanie A; Drucker, Daniel J; D'Alessio, David A; Campbell, Jonathan E; Müller, Timo D; Perez-Tilve, Diego; Finan, Brian; Knerr, Patrick J. (2026). Ectopic, hepatic GLP-1R agonism enhances the weight loss efficacy of GLP-1 analogues.. Molecular metabolism, 105, 102327. https://doi.org/10.1016/j.molmet.2026.102327